[
  {
    "sentence": "Figure 1 shows the flow diagram of the study selection process.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 shows the total and subgroup meta-analyses for the total HRQoL scores by the type of instrument.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A comparative meta-analysis of the 2 studies that provided sufficient information to directly compare the mean total HRQoL scores, as measured with EQ-5D-3L and PedsQL, between patients with and without FVIII inhibitors indicated a statistically significant increase in the SMD of HRQoL scores favoring patients without FVIII inhibitors (Supplementary Fig. 3; SMD = 0.57; 95% CI, 0.18-0.97; I2 = 0.0%) [32,40].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The meta-regression analysis also demonstrated that 3 of the 6 studies with the highest HRQoL scores (mean total Haemo-QoL score of <30) were treated with hemostatic agents such as turoctocog alfa (in 2 studies) and emicizumab (in 1 study) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Publication bias assessment revealed a highly heterogeneous yet fairly balanced distribution of data points in the funnel plot for the 14 studies that used the Haemo-QoL questionnaire (Supplementary Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Figure 1 shows the flow diagram of the study selection process.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 shows the total and subgroup meta-analyses for the total HRQoL scores by the type of instrument.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A comparative meta-analysis of the 2 studies that provided sufficient information to directly compare the mean total HRQoL scores, as measured with EQ-5D-3L and PedsQL, between patients with and without FVIII inhibitors indicated a statistically significant increase in the SMD of HRQoL scores favoring patients without FVIII inhibitors (Supplementary Fig. 3; SMD = 0.57; 95% CI, 0.18-0.97; I2 = 0.0%) [32,40].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The meta-regression analysis also demonstrated that 3 of the 6 studies with the highest HRQoL scores (mean total Haemo-QoL score of <30) were treated with hemostatic agents such as turoctocog alfa (in 2 studies) and emicizumab (in 1 study) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Publication bias assessment revealed a highly heterogeneous yet fairly balanced distribution of data points in the funnel plot for the 14 studies that used the Haemo-QoL questionnaire (Supplementary Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Figure 1 shows the flow diagram of the study selection process.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 shows the total and subgroup meta-analyses for the total HRQoL scores by the type of instrument.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A comparative meta-analysis of the 2 studies that provided sufficient information to directly compare the mean total HRQoL scores, as measured with EQ-5D-3L and PedsQL, between patients with and without FVIII inhibitors indicated a statistically significant increase in the SMD of HRQoL scores favoring patients without FVIII inhibitors (Supplementary Fig. 3; SMD = 0.57; 95% CI, 0.18-0.97; I2 = 0.0%) [32,40].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The meta-regression analysis also demonstrated that 3 of the 6 studies with the highest HRQoL scores (mean total Haemo-QoL score of <30) were treated with hemostatic agents such as turoctocog alfa (in 2 studies) and emicizumab (in 1 study) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Publication bias assessment revealed a highly heterogeneous yet fairly balanced distribution of data points in the funnel plot for the 14 studies that used the Haemo-QoL questionnaire (Supplementary Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Figure 1 shows the flow diagram of the study selection process.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 shows the total and subgroup meta-analyses for the total HRQoL scores by the type of instrument.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A comparative meta-analysis of the 2 studies that provided sufficient information to directly compare the mean total HRQoL scores, as measured with EQ-5D-3L and PedsQL, between patients with and without FVIII inhibitors indicated a statistically significant increase in the SMD of HRQoL scores favoring patients without FVIII inhibitors (Supplementary Fig. 3; SMD = 0.57; 95% CI, 0.18-0.97; I2 = 0.0%) [32,40].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The meta-regression analysis also demonstrated that 3 of the 6 studies with the highest HRQoL scores (mean total Haemo-QoL score of <30) were treated with hemostatic agents such as turoctocog alfa (in 2 studies) and emicizumab (in 1 study) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Publication bias assessment revealed a highly heterogeneous yet fairly balanced distribution of data points in the funnel plot for the 14 studies that used the Haemo-QoL questionnaire (Supplementary Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Figure 1 shows the flow diagram of the study selection process.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 shows the total and subgroup meta-analyses for the total HRQoL scores by the type of instrument.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A comparative meta-analysis of the 2 studies that provided sufficient information to directly compare the mean total HRQoL scores, as measured with EQ-5D-3L and PedsQL, between patients with and without FVIII inhibitors indicated a statistically significant increase in the SMD of HRQoL scores favoring patients without FVIII inhibitors (Supplementary Fig. 3; SMD = 0.57; 95% CI, 0.18-0.97; I2 = 0.0%) [32,40].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The meta-regression analysis also demonstrated that 3 of the 6 studies with the highest HRQoL scores (mean total Haemo-QoL score of <30) were treated with hemostatic agents such as turoctocog alfa (in 2 studies) and emicizumab (in 1 study) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Publication bias assessment revealed a highly heterogeneous yet fairly balanced distribution of data points in the funnel plot for the 14 studies that used the Haemo-QoL questionnaire (Supplementary Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Figure 1 shows the flow diagram of the study selection process.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 shows the total and subgroup meta-analyses for the total HRQoL scores by the type of instrument.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A comparative meta-analysis of the 2 studies that provided sufficient information to directly compare the mean total HRQoL scores, as measured with EQ-5D-3L and PedsQL, between patients with and without FVIII inhibitors indicated a statistically significant increase in the SMD of HRQoL scores favoring patients without FVIII inhibitors (Supplementary Fig. 3; SMD = 0.57; 95% CI, 0.18-0.97; I2 = 0.0%) [32,40].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The meta-regression analysis also demonstrated that 3 of the 6 studies with the highest HRQoL scores (mean total Haemo-QoL score of <30) were treated with hemostatic agents such as turoctocog alfa (in 2 studies) and emicizumab (in 1 study) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Publication bias assessment revealed a highly heterogeneous yet fairly balanced distribution of data points in the funnel plot for the 14 studies that used the Haemo-QoL questionnaire (Supplementary Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Figure 1 shows the flow diagram of the study selection process.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 shows the total and subgroup meta-analyses for the total HRQoL scores by the type of instrument.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A comparative meta-analysis of the 2 studies that provided sufficient information to directly compare the mean total HRQoL scores, as measured with EQ-5D-3L and PedsQL, between patients with and without FVIII inhibitors indicated a statistically significant increase in the SMD of HRQoL scores favoring patients without FVIII inhibitors (Supplementary Fig. 3; SMD = 0.57; 95% CI, 0.18-0.97; I2 = 0.0%) [32,40].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The meta-regression analysis also demonstrated that 3 of the 6 studies with the highest HRQoL scores (mean total Haemo-QoL score of <30) were treated with hemostatic agents such as turoctocog alfa (in 2 studies) and emicizumab (in 1 study) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Publication bias assessment revealed a highly heterogeneous yet fairly balanced distribution of data points in the funnel plot for the 14 studies that used the Haemo-QoL questionnaire (Supplementary Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Figure 1 shows the flow diagram of the study selection process.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 shows the total and subgroup meta-analyses for the total HRQoL scores by the type of instrument.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A comparative meta-analysis of the 2 studies that provided sufficient information to directly compare the mean total HRQoL scores, as measured with EQ-5D-3L and PedsQL, between patients with and without FVIII inhibitors indicated a statistically significant increase in the SMD of HRQoL scores favoring patients without FVIII inhibitors (Supplementary Fig. 3; SMD = 0.57; 95% CI, 0.18-0.97; I2 = 0.0%) [32,40].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The meta-regression analysis also demonstrated that 3 of the 6 studies with the highest HRQoL scores (mean total Haemo-QoL score of <30) were treated with hemostatic agents such as turoctocog alfa (in 2 studies) and emicizumab (in 1 study) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Publication bias assessment revealed a highly heterogeneous yet fairly balanced distribution of data points in the funnel plot for the 14 studies that used the Haemo-QoL questionnaire (Supplementary Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Figure 1 shows the flow diagram of the study selection process.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 shows the total and subgroup meta-analyses for the total HRQoL scores by the type of instrument.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A comparative meta-analysis of the 2 studies that provided sufficient information to directly compare the mean total HRQoL scores, as measured with EQ-5D-3L and PedsQL, between patients with and without FVIII inhibitors indicated a statistically significant increase in the SMD of HRQoL scores favoring patients without FVIII inhibitors (Supplementary Fig. 3; SMD = 0.57; 95% CI, 0.18-0.97; I2 = 0.0%) [32,40].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The meta-regression analysis also demonstrated that 3 of the 6 studies with the highest HRQoL scores (mean total Haemo-QoL score of <30) were treated with hemostatic agents such as turoctocog alfa (in 2 studies) and emicizumab (in 1 study) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Publication bias assessment revealed a highly heterogeneous yet fairly balanced distribution of data points in the funnel plot for the 14 studies that used the Haemo-QoL questionnaire (Supplementary Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Figure 1 shows the flow diagram of the study selection process.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2 shows the total and subgroup meta-analyses for the total HRQoL scores by the type of instrument.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A comparative meta-analysis of the 2 studies that provided sufficient information to directly compare the mean total HRQoL scores, as measured with EQ-5D-3L and PedsQL, between patients with and without FVIII inhibitors indicated a statistically significant increase in the SMD of HRQoL scores favoring patients without FVIII inhibitors (Supplementary Fig. 3; SMD = 0.57; 95% CI, 0.18-0.97; I2 = 0.0%) [32,40].",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The meta-regression analysis also demonstrated that 3 of the 6 studies with the highest HRQoL scores (mean total Haemo-QoL score of <30) were treated with hemostatic agents such as turoctocog alfa (in 2 studies) and emicizumab (in 1 study) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Publication bias assessment revealed a highly heterogeneous yet fairly balanced distribution of data points in the funnel plot for the 14 studies that used the Haemo-QoL questionnaire (Supplementary Fig. 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  }
]